Risk of pancreatic cancer in patients with systemic lupus erythematosus: a meta-analysis

Seo, Min Seok; Yeo, Jina; Hwang, In Cheol; Shim, Jae Yong

doi:10.1007/s10067-019-04660-9

Cited by 13 publications

(13 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a meta-analysis of 11 cohort studies, patients with systemic lupus erythematosus were found to be an increased risk for developing pancreatic cancer (CI 1.32-1.53, hazard ratio [HR], 1.43). 40 However, further epidemiologic studies involving careful evaluation of these possible risk factors with adjustments for potential confounders are needed to clarify their impact on pancreatic cancer risk.…”

Section: Risk Factors and Genetic Predispositionmentioning

confidence: 99%

Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology

Tempero

Malafa

Al-Hawary

et al. 2021

Journal of the National Comprehensive Cancer Network

711

536

View full text Add to dashboard Cite

Pancreatic cancer is the fourth leading cause of cancer-related death among men and women in the United States. A major challenge in treatment remains patients’ advanced disease at diagnosis. The NCCN Guidelines for Pancreatic Adenocarcinoma provides recommendations for the diagnosis, evaluation, treatment, and follow-up for patients with pancreatic cancer. Although survival rates remain relatively unchanged, newer modalities of treatment, including targeted therapies, provide hope for improving patient outcomes. Sections of the manuscript have been updated to be concordant with the most recent update to the guidelines. This manuscript focuses on the available systemic therapy approaches, specifically the treatment options for locally advanced and metastatic disease.

show abstract

Section: Risk Factors and Genetic Predispositionmentioning

confidence: 99%

Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology

Tempero

Malafa

Al-Hawary

et al. 2021

Journal of the National Comprehensive Cancer Network

711

536

View full text Add to dashboard Cite

show abstract

“…The results of a meta-analysis conducted by Seo M.S. reported that patients with systemic lupus erythematosus may have a risk of developing PC as well [ 71 ].…”

Section: Pancreatic Cancer Risk Factorsmentioning

confidence: 99%

Targeting PI3K/AKT/mTOR Signaling Pathway in Pancreatic Cancer: From Molecular to Clinical Aspects

Stanciu¹,

Ioniţă-Radu²,

Ştefani³

et al. 2022

IJMS

View full text Add to dashboard Cite

Although pancreatic cancer (PC) was considered in the past an orphan cancer type due to its low incidence, it may become in the future one of the leading causes of cancer death. Pancreatic ductal adenocarcinoma (PDAC) is the most frequent type of PC, being a highly aggressive malignancy and having a 5-year survival rate of less than 10%. Non-modifiable (family history, age, genetic susceptibility) and modifiable (smoking, alcohol, acute and chronic pancreatitis, diabetes mellitus, intestinal microbiota) risk factors are involved in PC pathogenesis. Chronic inflammation induced by various factors plays crucial roles in PC development from initiation to metastasis. In multiple malignant conditions such as PC, cytokines, chemokines, and growth factors activate the class I phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) (PI3K/AKT/mTOR) signaling pathway, which plays key roles in cell growth, survival, proliferation, metabolism, and motility. Currently, mTOR, AKT, and PI3K inhibitors are used in clinical studies. Moreover, PI3K/mTOR dual inhibitors are being tested in vitro and in vivo with promising results for PC patients. The main aim of this review is to present PC incidence, risk factors, tumor microenvironment development, and PI3K/AKT/mTOR dysregulation and inhibitors used in clinical, in vivo, and in vitro studies.

show abstract

“…Other modifiable risk factors with probable or convincing evidence are cigarette smoking, heavy alcohol consumption, increased Body Mass Index (BMI) and abdominal obesity [ 9 , 10 ], chronic pancreatitis, Diabetic Mellitus (DM), hepatitis B, cholecystectomy [ 11 , 12 ], and periodontal disease. Nevertheless, there were still other ambiguous risk factors with inconclusive evidence, such as increased consumption of processed meat, Helicobacter Pylori infection, and Systemic Lupus Erythematosus (SLE) history [ 13 , 14 ]. It has thus been suggested that 37% of pancreatic cancer patients in the United Kingdom can be prevented [ 15 ].…”

Section: Introductionmentioning

confidence: 99%

Risk Factors Associated with Pancreatic Cancer in the UK Biobank Cohort

Lophatananon

Muir

2022

Cancers

View full text Add to dashboard Cite

Evidence on pancreatic cancer (PaCa) risk factors from large population-based cohort studies is limited. This study investigated the PaCa risk factors and the population attributable fraction (PAF) of modifiable risk factors in the UK Biobank cohort. The UK Biobank is a prospective cohort consisting of 502,413 participants with a mean follow-up time of 8.2 years. A binomial generalized linear regression model was used to calculate relative risks for PaCa risk factors. PAF was calculated to estimate the proportional reduction in PaCa if modifiable risk factors were to be eliminated. A total of 728 (0.14%) PaCa incident cases and 412,922 (82.19%) non-PaCa controls were analyzed. The non-modifiable risk factors included age and gender. The modifiable risk factors were cigarette smoking, overweight and obesity, increased waist circumstance, abdominal obesity, Diabetic Mellitus (DM), and pancreatitis history. The PAF suggested that eliminating smoking and obesity can contribute around a 16% reduction in PaCa cases while avoiding abdominal obesity can eliminate PaCa cases by 22%. Preventing pancreatitis and DM could potentially reduce PaCa cases by 1% and 6%, respectively. This study has identified modifiable and non-modifiable PaCa risk factors in the UK population. The PAF of modifiable risk factors can be applied to inform PaCa prevention programs.

show abstract

Risk of pancreatic cancer in patients with systemic lupus erythematosus: a meta-analysis

Cited by 13 publications

References 42 publications

Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology

Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology

Targeting PI3K/AKT/mTOR Signaling Pathway in Pancreatic Cancer: From Molecular to Clinical Aspects

Risk Factors Associated with Pancreatic Cancer in the UK Biobank Cohort

Contact Info

Product

Resources

About